Physician profile
Wesley A Parker
NPI 1790780476
$723.38
in general payments reported to CMS, 2019-2025
14 companies · $16.50 in 2025
The $16.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $72.78 · 2021: $134 · 2022: $108 · 2023: $16.42 · 2024: $32.52 · 2025: $16.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.65 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.65 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $237.64 | 2019-2021 | |
| Amgen INC. | $226.12 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $38.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.66 | 2021 | |
| Novo Nordisk INC | $33.44 | 2019 | |
| Pfizer INC. | $24.71 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Eisai INC. | $16.94 | 2022 | |
| Baxter Healthcare | $15.87 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $14.14 | 2019 | |
| Glaxosmithkline, LLC. | $12.09 | 2022 | |
| Medtronic Minimed, INC. | $11.98 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.